US physicians to increase use of Zytiga in chemo-naive prostate cancer patients

Physicians in the USA said they would use Zytiga (abiraterone acetate), from health care giant Johnson & Johnson’s (NYSE: JNJ) Janssen subsidiary, in more than half of their castrate-resistant prostate cancer (CRPC) patients who are asymptomatic or minimally symptomatic in the pre-chemotherapy setting, according to a survey conducted by Kantar Health, a health care-focused consultancy.

Kantar Health conducted a brief survey with US oncologists before and after the recent meeting of the American Society of Clinical Oncology (ASCO) to determine how the presentation of clinical data at the recent meeting would affect oncologists’ use of oncology treatments.

Influenced by ASCO presentations